Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

DiaMedica Therapeutics (DMAC) EBITDA Margin (2018)

DiaMedica Therapeutics' EBITDA Margin history spans 1 years, with the latest figure at 277.4% for Q3 2018.

  • For Q3 2018, EBITDA Margin changed N/A year-over-year to 277.4%; the TTM value through Jun 2019 reached 1811.8%, changed N/A, while the annual FY2025 figure was 327390.0%, 25554588.0% up from the prior year.
  • EBITDA Margin reached 277.4% in Q3 2018 per DMAC's latest filing.
  • In the past five years, EBITDA Margin ranged from a high of 277.4% in Q3 2018 to a low of 277.4% in Q3 2018.